Clinical trials · Nashville, TN
Cancer clinical trials in Nashville
We’re tracking 453 recruiting cancer studies with a site in or near Nashville — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Nashville
- NCT06990880RecruitingPhase 1/Phase 2
Study of GSK5458514 alone or with other drugs for prostate cancer
This trial tests a new drug, GSK5458514, either alone or with other cancer treatments, for men with advanced prostate cancer that has stopped responding to standard therapies. The goal is to see if the drug can slow down the cancer.
Nashville, TennesseeAges 18 years+ - NCT06748222RecruitingPhase 3
Online mindfulness program for breast cancer survivors
This trial tests a 6-week online mindfulness program to help breast cancer survivors manage mild to moderate depression. You may qualify if you finished active treatment within the last 5 years and can use a digital device.
Nashville, TennesseeAges 18–50 - NCT07001748RecruitingPhase 2/Phase 3
Testing abdominal chemo plus standard chemo for stomach cancer spread
This trial tests adding the chemotherapy drug paclitaxel directly into the abdomen (intraperitoneal) along with standard IV chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen. The goal is to see if this combination helps control the cancer better than standard treatment alone.
Nashville, TennesseeAges 18 years+ - NCT07003295RecruitingPhase 2
Glofitamab for mantle cell lymphoma that returned after CAR-T
This trial tests a new drug, glofitamab, for mantle cell lymphoma that came back or didn’t respond after CAR-T cell therapy. It aims to see if glofitamab can shrink or control the lymphoma.
Nashville, TennesseeAges 18 years+ - NCT07288177RecruitingPhase 2
A study of Rina-S for people with non-small cell lung cancer
This trial tests a new drug called Rina-S for people with non-small cell lung cancer that has spread or can't be removed by surgery. It aims to see if the drug can shrink tumors and how safe it is.
Nashville, TennesseeAges 18 years+ - NCT07227415RecruitingPhase 1/Phase 2
Study of a new drug for advanced kidney cancer
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
Nashville, TennesseeAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Nashville, TennesseeAges 18 years+ - NCT07016399RecruitingPhase 2
Darolutamide before surgery for AR-positive triple-negative breast cancer
This trial tests a drug called darolutamide, alone or with standard chemotherapy, before surgery for a type of breast cancer that is triple-negative but has a high level of the androgen receptor (AR). It is for people with stage II or IIIA breast cancer that can be removed surgically.
Nashville, TennesseeAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
Nashville, TennesseeAges 18 years+ - NCT06577987RecruitingPhase 1
Study of CID-078 for advanced solid tumors
This trial tests an experimental drug called CID-078 for people with advanced solid tumors that have stopped responding to other treatments. It aims to find the right dose and see if the drug can shrink tumors.
Nashville, TennesseeAges 12 years+ - NCT06875310RecruitingPhase 3
Study of adagrasib plus pembrolizumab plus chemotherapy for KRAS G12C lung cancer
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
Nashville, TennesseeAges 18 years+ - NCT07611110RecruitingPhase 3
AZD2265 vs standard care for advanced prostate cancer
This trial tests a new cancer-fighting drug called AZD2265 against standard treatment for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. You may qualify if your cancer previously responded to PSMA-targeted radiation treatments but is now growing again.
Nashville, TennesseeAges 18 years+ - NCT06827613RecruitingPhase 1/Phase 2
Study of invikafusp alfa plus sacituzumab govitecan for advanced solid tumors
This trial tests a new drug combination for people with advanced breast cancer (triple-negative or hormone receptor-positive). The goal is to see if the combination helps shrink tumors or slow their growth.
Nashville, TennesseeAges 18 years+ - NCT06567743RecruitingPhase 2
Study of a new virus therapy for high-risk bladder cancer
This trial tests a new virus-based medicine, cretostimogene grenadenorepvec, given directly into the bladder for people with high-risk non-muscle-invasive bladder cancer. It may help prevent the cancer from coming back, especially for those who have not had BCG treatment or whose cancer did not respond to BCG.
Nashville, TennesseeAges 18 years+ - NCT07090499RecruitingPhase 1
Study of PF-08046876 for advanced solid tumors
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
Nashville, TennesseeAges 18 years+ - NCT04410796RecruitingPhase 2
Osimertinib alone or with chemo for EGFR-mutant lung cancer
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
Nashville, TennesseeAges 18 years+ - NCT05803382RecruitingPhase 1
Adding a new drug to capecitabine for metastatic colorectal cancer
This Phase 1 study tests a new anti-cancer drug (ZEN003694) added to the usual chemotherapy capecitabine. It is for adults with colorectal cancer (and possibly other cancers) that has spread or cannot be removed and has continued despite prior standard treatment.
Nashville, TennesseeAges 18 years+ - NCT07097142RecruitingPhase 3
Shorter radiation for bladder cancer with chemo
This trial tests if a shorter course of radiation therapy works as well as the usual longer course for people with bladder cancer who are also receiving standard chemotherapy. The goal is to see if shorter treatment can reduce side effects while still being effective.
Nashville, TennesseeAges 18 years+ - NCT06561685RecruitingPhase 1
Study of LY4050784 for Advanced Solid Tumors with SMARCA4 Changes
This trial tests a new drug, LY4050784, for people with advanced solid tumors that have a specific change in a gene called SMARCA4 (BRG1). The study aims to see if the drug is safe and effective. It may be an option for those who have tried other treatments or have no standard options left.
Nashville, TennesseeAges 18 years+ - NCT07109726RecruitingPhase 1/Phase 2
Testing TER-2013 for advanced tumors with AKT/PI3K/PTEN changes
This trial tests a new drug called TER-2013, alone or combined with another drug (fulvestrant), for people with advanced solid tumors that have specific genetic changes in the AKT/PI3K/PTEN pathway. It aims to see if the drug is safe and effective.
Nashville, TennesseeAges 18 years+ - NCT07287917RecruitingPhase 1/Phase 2
Testing a new drug combo for advanced breast cancer or melanoma
This trial tests a new combination of drugs (AMXT 1501, DFMO, and standard therapies) for people with advanced solid tumors, specifically breast cancer (ER+ HER2-) or melanoma that has progressed after other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Nashville, TennesseeAges 18 years+ - NCT06380751RecruitingPhase 3
New targeted therapy for BRCA/PALB2-mutated HR+ breast cancer
This trial tests a new combination of targeted therapies (saruparib plus camizestrant or hormone therapy) against standard treatments for people with a specific type of advanced breast cancer. It may be a good option if you have a BRCA1, BRCA2, or PALB2 gene mutation and have not yet had treatment for your advanced disease.
Nashville, TennesseeAges 18 years+ - NCT06046495RecruitingPhase 1
Study of an oral EGFR inhibitor for non-small cell lung cancer
This trial tests PLB1004, an oral medication that targets a specific gene mutation (EGFR) in non-small cell lung cancer. It may be an option if you have this mutation and are looking for a new treatment.
Nashville, TennesseeAges 18 years+ - NCT07555210Recruiting
Bone Density Changes During Cancer Immunotherapy
This study tracks how a type of cancer treatment called anti-PD-1 immunotherapy affects bone strength over time. Researchers want to understand whether this treatment causes bone density loss and help develop ways to protect bones during cancer care.
Nashville, TennesseeAges 18 years+
Hear when a new Cancer trial opens near Nashville, TN
We’ll email you when one opens near Nashville, TN — at most once a week, no account needed, unsubscribe anytime.
Cancer trials in other cities
Where these studies are running near Nashville
Institutions with a site for the recruiting cancer studies listed above.
- Vanderbilt University Medical Center · 9 studies
- Sarah Cannon Research Institute · 8 studies
- SCRI Oncology Partners · 7 studies
- Research Site · 2 studies
- Tennessee Oncology · 2 studies
- Exelixis Clinical Site
- GSK Investigational Site
- Local Institution - 0697
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting cancer studies in Tennessee.
Common questions
- Are there cancer clinical trials near Nashville?
- Yes. We're currently tracking 453 recruiting cancer studies with a site near Nashville, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study near Nashville?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Nashville to take part?
- Not necessarily. These studies have a site near Nashville, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open near Nashville regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.